- Home
- STTK vs TEAF Comparison
STTK vs TEAF Comparison
Compare STTK & TEAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- TEAF
- Stock Information
- Founded
- STTK 2016
- TEAF 2017
- Country
- STTK United States
- TEAF United States
- Employees
- STTK N/A
- TEAF N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- TEAF Trusts Except Educational Religious and Charitable
- Sector
- STTK Health Care
- TEAF Finance
- Exchange
- STTK Nasdaq
- TEAF Nasdaq
- Market Cap
- STTK 173.6M
- TEAF 165.2M
- IPO Year
- STTK 2020
- TEAF N/A
- Fundamental
- Price
- STTK $3.86
- TEAF $12.74
- Analyst Decision
- STTK Strong Buy
- TEAF
- Analyst Count
- STTK 3
- TEAF 0
- Target Price
- STTK $10.67
- TEAF N/A
- AVG Volume (30 Days)
- STTK 150.7K
- TEAF 56.1K
- Earning Date
- STTK 11-07-2024
- TEAF 01-01-0001
- Dividend Yield
- STTK N/A
- TEAF 9.20%
- EPS Growth
- STTK N/A
- TEAF N/A
- EPS
- STTK N/A
- TEAF N/A
- Revenue
- STTK $4,123,999.00
- TEAF N/A
- Revenue This Year
- STTK $164.45
- TEAF N/A
- Revenue Next Year
- STTK N/A
- TEAF N/A
- P/E Ratio
- STTK N/A
- TEAF N/A
- Revenue Growth
- STTK 380.09
- TEAF N/A
- 52 Week Low
- STTK $1.33
- TEAF $11.11
- 52 Week High
- STTK $11.76
- TEAF $13.30
- Technical
- Relative Strength Index (RSI)
- STTK 57.18
- TEAF 70.77
- Support Level
- STTK $3.37
- TEAF $12.18
- Resistance Level
- STTK $3.75
- TEAF $12.37
- Average True Range (ATR)
- STTK 0.24
- TEAF 0.12
- MACD
- STTK 0.08
- TEAF 0.04
- Stochastic Oscillator
- STTK 88.57
- TEAF 93.36
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.
About TEAF Ecofin Sustainable and Social Impact Term Fund
Tortoise Essential Assets Income Term is a US-based non-diversified, closed-end management investment company. Its investment objective is to provide common shareholders with a high level of total return with an emphasis on current distributions.